Order Article Reprints

Kardas P, Lichwierowicz A, Urbański F, Szadkowska-Opasiak B, Karasiewicz E, Lewek P, Krupa D, Czech M. The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis. Pharmaceutics. 2021; 13(8):1165. https://doi.org/10.3390/pharmaceutics13081165

Kardas, Przemysław, Aneta Lichwierowicz, Filip Urbański, Beata Szadkowska-Opasiak, Ewa Karasiewicz, Paweł Lewek, Dominika Krupa, and Marcin Czech. 2021. "The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis" Pharmaceutics 13, no. 8: 1165. https://doi.org/10.3390/pharmaceutics13081165

Kardas, P., Lichwierowicz, A., Urbański, F., Szadkowska-Opasiak, B., Karasiewicz, E., Lewek, P., Krupa, D., & Czech, M. (2021). The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis. Pharmaceutics, 13(8), 1165. https://doi.org/10.3390/pharmaceutics13081165